Welcome!‎ > ‎

Publications

2017
   England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, Barnhart TE, McNeel DG, Huang P, Cai W. Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):110-120. doi: 10.1007/s00259-017-3803-4. PMID: 28821924

    McNeel DG. Therapeutic Cancer Vaccines: How Much Closer Are We? BioDrugs. 2017 Dec 28. doi: 10.1007/s40259-017-0257-y. PMID: 29285731

    Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HE, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC. A First-in-Human Phase 1 Study of Subcutaneous Outpatient Recombinant Human IL-15 (rhIL-15) in Adults with Advanced Solid Tumors. Clin Cancer Res. 2017 Dec 4. pii: clincanres.2451.2017. doi: 10.1158/1078-0432.CCR-17-2451. PMID: 29203590

    Olson BM, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, Drake CG, Weichert J, McNeel DG. Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells. Cancer Immunol Res. 2017 Dec;5(12):1074-1085. doi: 10.1158/2326-6066.CIR-16-0390. PMID: 29051161

    Gamat M, McNeel DG. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer. 2017 Dec;24(12):T297-T310. doi: 10.1530/ERC-17-0145. Review. PMID: 28814451

    Zahm CD, Colluru VT, McNeel DG. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells. Cancer Immunol Res. 2017 Aug;5(8):630-641. doi: 10.1158/2326-6066.CIR-16-0374. PMID: 28634215

    Johnson LE, Olson BM, McNeel DG. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. J Immunother Cancer. 2017 Jul 18;5(1):56. doi: 10.1186/s40425-017-0260-3. PMID: 28716080

    Zahm CD, Colluru VT, McNeel DG. DNA vaccines for prostate cancer. Pharmacol Ther. 2017 Jun;174:27-42. doi: 10.1016/j.pharmthera.2017.02.016. Review. PMID: 28185916

    Ehlerding EB, England CG, Majewski RL, Valdovinos HF, Jiang D, Liu G, McNeel DG, Nickles RJ, Cai W. ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. Mol Pharm. 2017 May 1;14(5):1782-1789. doi: 10.1021/acs.molpharmaceut.7b00056. PMID: 28388076

    Olson BM, Bradley ES, Sawicki T, Zhong W, Ranheim EA, Bloom JE, Colluru VT, Johnson LE, Rekoske BT, Eickhoff JC, McNeel DG. Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD). Prostate. 2017 May;77(7):812-821. doi: 10.1002/pros.23321. PMID: 28181678

    England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2017 Jan;58(1):162-168. doi: 10.2967/jnumed.116.177857. PMID: 27493273

    McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016 Dec 20;4:92. doi: 10.1186/s40425-016-0198-x. eCollection 2016. PMID: 28031820

    Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, Jarrard DF, McNeel DG, Lang JM. Inducible expression of cancer-testis antigens in human prostate cancer.  Oncotarget. 2016 Dec 20;7(51):84359-84374. doi: 10.18632/oncotarget.12711. PMID: 27769045

2016

    McNeel DG. TCR diversity - a universal cancer immunotherapy biomarker? J Immunother Cancer. 2016 Nov 15;4:69. PMID: 27879971

    Colluru VT, Zahm CD, McNeel DG. Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses. Oncoimmunology. 2016 Sep 2;5(10):e1223002. PMID: 27853647

    Colluru VT, McNeel DG. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Oncotarget. 2016 Sep 21. doi: 10.18632/oncotarget.12178. PMID: 27661128 

    Rekoske BT, McNeel DG. Immunotherapy for prostate cancer: False promises or true hope? Cancer. 2016 Dec 1;122(23):3598-3607. doi: 10.1002/cncr.30250. PMID: 27649312

    Rekoske BT, Olson BM, McNeel DG. Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology. 2016 Mar 28;5(6):e1165377. doi: 10.1080/2162402X.2016.1165377. PMID: 27471641

    Bloom JE, McNeel DG. SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget. 2016 Jun 2. doi: 10.18632/oncotarget.9802. PMID: 27276714

    Colluru VT, Johnson LE, Olson BM, McNeel DG. Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Review. PMID: 24332642

    Bradley ES and McNeel DG. “DNA Vaccines.” Marshall JL ed. Encyclopedia of Cancer Therapeutic Targets. New York: Springer, 2016.

2015
    McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, DiPaola RS. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother 2015;11(10):2469-74. doi: 10.1080/21645515. 2015.1062190. PMID: 26111351

    Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DGPD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res. 2015 Aug;3(8):946-55. doi: 10.1158/2326-6066.CIR-14-0206. Epub 2015 Jun 3. PMID: 26041735


2014
        McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM.  Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.  Clin Cancer Res.  2014 Jul 15;20(14):3692-704. doi: 10.1158/1078-0432.

        Smith HA, Rekoske BT, McNeel DG. DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine. 2014 Mar 26;32(15):1707-15. doi: 10.1016/j.vaccine.2014.01.048. 

2013
        Olson BM, McNeel DG. Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol. 2013 May 6;3:109. doi: 10.3389/fonc.2013.00109.

        Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG.  A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.Clin Genitourin Cancer. 2013 Dec;11(4):407-15. doi: 10.1016/j.clgc.2013.04.029. 

         Johnson LE, Becker JT, Dubovsky JA, Olson BM, McNeel DGProstate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. Chin Clin Oncol. 2013 Mar 1;2(1). doi: 10.3978/j.issn.2304-3865.2012.11.06.

        Becker JT, McNeel DG. Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.  J Immunother Cancer. 2013 May 29;1:2. doi: 10.1186/2051-1426-1-2.

        Casavant BP, Mosher R, Warrick JW, Maccoux LJ, Berry SM, Becker JT, Chen V, Lang JM, McNeel DG, Beebe DJ.  A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells.  Methods. 2013 Dec 1;64(2):137-43. doi: 10.1016/j.ymeth.2013.05.027.

        Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG.Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol. 2012 Dec 15;189(12):5590-601. doi: 10.4049/jimmunol.1201744  

        Bloom JE, McNeel DG, and Olson BM.  Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.Expert Rev Vaccines. 2012 Dec;11(12):1401-4. doi: 10.1586/erv.12.122.

        Johnson LE, Frye TP, McNeel DGImmunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology. 2012 Dec 1;1(9):1546-1556.     

       Olson BM and McNeel DG.  Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence.  Expert Rev Vaccines. 2012 Nov;11(11):1315-7. doi: 10.1586/erv.12.107.

       McNeel DG, Becker JT, Johnson LE, and Olson BM.  DNA Vaccines for Prostate Cancer.Curr Cancer Ther Rev. 2012 Nov 1;8(4):254-263.
        Bruce JY, Lang JM, McNeel DG, Liu G.  Current controversies in the management of biochemical failure in prostate cancer.  Clin Adv Hematol Oncol. 2012 Nov;10(11):716-22.

        Smith HA and McNeel DG. (2010) “The SSX family of cancer-testis antigens as target proteins for tumor therapy.” Clin. Dev. Immunol. 2010:150591.

        Alam S and McNeel DG. (2010) “DNA vaccines for the treatment of prostate cancer.” Exp. Rev. Vaccines 9:731-745.

        Gao JJ, Maricque BB, Morse MD, Huang W, and McNeel DG. (2010) “Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease.” J. Clin. Oncol. 28:e680-683.

        Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, and McNeel DG. (2010) “DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.” J Immunotherapy 33:639-647.

        Morse MD and McNeel DG. (2010) “Prostate cancer patients treated with androgen deprivation therapy develop persistent changes in adaptive immune responses.” Human Immunology 71:496-504.

 
2009

1.      Comments on McNeel DG (2009) J. Clin. Oncol. 27:4047-4054

a.       Drake CG.  (2009)  “Immunotherapy for prostate cancer:  walk, don’t run.”  J. Clin. Oncol. 27:4035-4037

b.      Smith MR and Kantoff PW.  (2010)  “Changes in PSA kinetics after DNA vaccine therapy – not so fast!”  J. Clin. Oncol. 28:e58


 
2007
        Ward J and McNeel DG. (2007) “GVAX: An allogeneic, whole-cell, GM-CSF-secreting vaccine for the treatment of prostate cancer.” Exp. Opin. Biol. Ther. 7:1893-1902.

        Kipp RT and McNeel DG. (2007) “Immunotherapy of prostate cancer.” Clin. Adv. Hem. Onc. 5:465-479.

        McNeel DG. (2007) “Prostate cancer immunotherapy.” Curr. Opin. Urol. 17:175-181.

        McNeel DG. (2007) “Cellular immunotherapies for prostate cancer.” Biomed Pharmacother. 61:315-322.

        Dubovsky JA and McNeel DG. (2007) “Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.” Prostate 67:1781-1790.

        Olson BM and McNeel DG. (2007) “Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.” Prostate 67:1729-1739.

        Dubovsky JA, Albertini MR and McNeel DG. (2007) “MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis.” J. Immunotherapy 30:675-683.

        Johnson LE, Frye TP, Chinnasamy D, Chinnasamy N, and McNeel DG. (2007) “Plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) effective in eliciting autologous antigen-specific CD8 T cells.” Cancer Immunol Immunother 56:885-895.
 
2006
        Dunphy EJ, Johnson LE, Olson BM, Frye TP, and McNeel DG. (2006) “New approaches to identification of antigenic candidates for future prostate cancer immunotherapy.” Update on Cancer Therapeutics 22:273-284.

        Hoeppner LH, Dubovsky JA, Dunphy EJ, and McNeel DG. (2006) “Humoral immune responses to testis antigens in sera from patients with prostate cancer.” Cancer Immun. [serial online] 6:1-7.

        Mooney CJ, Dunphy EJ, Stone B, and McNeel DG. (2006) “Prostate cancer presenting as dermatomyositis: Case report and immunological analysis.” Int. J. Urol. 13:211-217.

        Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, and McNeel DG. (2006) “Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).” Vaccine 24:293-303.

2005
        McNeel DG and Malkovsky M. (2005) “Immune-based therapies for prostate cancer.” Immunol. Lett. 96:3-9.

        McNeel DG. “Prostate cancer antigens and vaccines, preclinical developments.” In: Giaccone G, Schilsky R, Sondel P. eds. Cancer Chemotherapy and Biological Response Modifiers, Annual 22. Oxford: Elsevier Limited, 2005 p. 247-261.

        Dunphy EJ and McNeel DG. (2005) “Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand.” J. Immunotherapy 28:268-275.

2004
        Dunphy EJ, Eickhoff JC, Muller CH, Berger RE, and McNeel DG. (2004) “Identification of antigen-specific IgG in sera from patients with chronic prostatitis.” J. Clin. Immunol. 24:492-502.
Comments